Overview

The practice of pediatric nephrology involves taking care of rare diseases in an ever-changing scientific landscape. The goal of our activity is to improve the education of our section in the practice of pediatric nephrology through discussion of relevant nephrology topics, new scientific literature, understanding standard of care, and working with other divisions that see overlapping disease processes.

Wednesday, March 19, 2025

Time: 2:30 -3:30 pm

Topic: Clinical practice standardization: Hyperammonemia at CHCO

Presenters:
Vivian Shih, MD. Pediatric Nephrology. Medical Director.
Erica Wymore, MD Pediatric Neonatology/Perinatology.

Objectives

• Deliver educational content on topics directly relevant to pediatric nephrology practice.
• Analyze pediatric nephrology scientific literature to improve critical appraisal skills.
• Apply evidence-based strategies to inform clinical practice patterns for hyper-specialized populations in pediatric nephrology.
• Present key nephrology topics to other hospital sections to improve interdisciplinary understanding.

Target Audience:

MD/DO

Continuing Education Credit

Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosures 

Bradley Dixon, MD, has disclosed financial relationships with:

• Apellis Pharmaceuticals- Consultant, Research Funding
• Alexion Astra Zeneca- Consultant, Research Funding
• Novartis Pharmaceuticals- Consultant, Research Funding
• Arrowhead Pharmaceuticals- Consultant
• Calliditas Therapeutics- Consultant
• Roche Genentech Group- Research Funding

All of the relevant financial relationships listed have been mitigated.

All other planners, faculty, and content reviewers have no relevant financial relationships with ineligible companies.